The Multidisciplinary Association for Psychedelic Studies (MAPS) is a U.S.-based non-profit organization that assists scientists to design, fund, obtain approval for and report on studies into the risks and benefits of psychedelic drugs (including MDMA, ibogaine and cannabis).
MAPS' mission is to develop these drugs into FDA-approved prescription medicines, and to educate the public about their risks and benefits. MAPS has often been at odds with the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) in their efforts to research the medicinal purposes of cannabis. MAPS founder Rick Doblin claims that NIDA is "scared of the research" MAPS is performing. MAPS has a $5 million, 5 year plan to conduct the research necessary to obtain FDA approval for MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD). In addition to its research efforts, MAPS has recently published six books, and publishes a quarterly journal, the MAPS Bulletin.
The organization was founded by Rick Doblin in 1986.